Prime Medicine is eliminating 25% of its workforce in a restructuring that includes the company pivoting its prime editing-based pipeline focus to liver disease and programs funded by external ...

AI evolves beyond mere algorithms to open up new frontiers in generative AI and agentic AI, and the art of the possible is ...

Artificial intelligence is changing the skills needed to succeed. A digitally-literate workforce is absolutely critical.

Regeneron to acquire nearly all of 23andMe’s assets for $256M, marking a new chapter for the direct-to-consumer genetic testing pioneer.

10x Genomics has settled patent infringement lawsuits with a pair of rivals, Bruker and Vizgen, through settlements that could reshape competition within the emerging single-cell and spatial genomics ...

This is the first gene editor to use a CRISPR-associated transposase to make targeted edits at therapeutically useful levels in humans.

Element has responded to the lawsuit with a statement saying, “Element is proud of its strong history of innovation. We are ...

BioMarin agreed to shell out approximately $270 million for Inozyme Pharma, a developer whose treatments target the PPi-adenosine pathway, a key regulator of bone health and blood vessel function.

How malaria parasites exploit mechanism for escaping elimination could provide novel strategies targeting chronic malaria ...

In addition to complementing AAV manufacturing, the company’s Plasmid DNA (pDNA) platform is now available as a standalone service.

Scientists say study findings indicate that TC IV cells may represent a therapeutic target for the treatment of ...

Researchers were able to test how viruses replicate differently across various bat species and organs using the new organoid ...